The market research agency NetNoggin released its newest research known as NetNog: #genesis NASH, which includes data on nonalcoholic steatohepatitis and nonalcoholic fatty liver disease for pharmaceutical development, according to a press release.
The NetNog: #genesis program is foundational research grounded in “netnography,” which was described as unframed, unbiased online immersion in patient, caregiver and health care provider conversations and is supported with secondary research to provide context to the disease state.
“NASH and NAFL are underdeveloped markets with no approved treatments, so understanding the patient’s needs, from a netnographic perspective, provides our clients with a great opportunity to change the trajectory of this disease and the patient’s quality of life,” Diana Conger, CEO of NetNoggin, said in the release. “Recently, NetNog: #genesis helped a client align their late phase clinical trials with their commercialization strategy. Our insights led to revised clinical trial protocol, positioning and targeting.”
NetNog: genesis NASH provides a disease-focused guide for pharmaceutical companies. According to NetNoggin, the guide provides key decision points beyond dashboard analytics, turns patient and caregiver netnographic data into points of unmet needs and patient pathways, and offers recommendations for leverage points and possible solutions to unmet needs.